AlphAIAlphAI — Financial news for AI agents
investors.com$ZTS

Milo's Drugmaker Barks Up A Third-Quarter Beat

Zoetis (ZTS) reported Q3 adjusted earnings of $1.75 per share on $2.39B in sales, beating analyst estimates. This compares to $1.70 per share on $2.42B in sales a year earlier. The company's stock rose early Thursday following the announcement.

Original reporting
investors.com
Published Nov 5, 2026, 1:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 3:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ZTS
Bullish
high confidence
Mentioned
$ZTS
Relevance
8/10
AlphAI data visualization · based on investors.com
Decision brief

The 30-second read

$ZTSBullishMed
01

Why it matters

Earnings beat suggests continued demand for companion‑animal products and may trigger short‑term buying.

02

Market read

Zoetis' earnings beat provides a fresh catalyst for the stock and its sector.

03

What to watch

Potential supply‑chain constraints in the pet‑care market could temper future growth.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Zoetis is the leading global animal health company, listed on NYSE under ZTS.

Company-level read

Ticker impact

$ZTSBullishHigh confidence
Context

Zoetis reported Q3 earnings of $1.75 EPS on $2.39B sales, beating expectations of $1.51 EPS and $2.3B sales.

Expected impact

likely upward pressure as the market prices in the earnings beat

Evidence & confidence

The beat is material and the company is mid‑cap; investors typically react positively to better‑than‑expected earnings.

Market effects

Sector

Strong performance may lift the broader animal health sector.

Regional

U.S. market may see modest gains in health‑care stocks.

Global

Limited to investors tracking pet‑care and biotech segments.

Counterpoint

What could challenge this read

If guidance remains flat, the beat may be priced in quickly, limiting upside.

Key entities

  • company
    Zoetis

    Global animal health firm reporting Q3 results.

Read at source← All news

StoryZoetis reports Q3 2026 results, beats EPS and raises full‑year guidance

Also covered by

5 outlets

Related articles

$ZTSMedAI 8/10

Zoetis (ZTS) Q3 2026 Earnings Call Transcript

Zoetis (ZTS) reported Q3 2026 earnings with revenue and adjusted net income declining as expected. The company cited challenges in pet care due to rising costs and changing pet ownership trends, while livestock demand remains strong. Zoetis narrowed its full-year revenue guidance to the high end of its range and highlighted investments in key franchises and innovation.

finance.yahoo.com
$ZTSMedAI 8/10

Zoetis 3Q 2026: Revenue $2.39B, EPS $1.44 — 10-Q Summary

Zoetis reported 3Q 2026 revenue of $2.39B, down 1% YoY, and net income of $1.44B, down 18%. Declines were driven by softer U.S. companion-animal demand, competition, and lower prices, partially offset by livestock growth and favorable exchange rates. Higher restructuring costs also impacted earnings. U.S. companion-animal revenue fell 8%, while U.S. livestock and international revenues rose 5% and 4%, respectively.

tradingview.com
$ZTSHighAI 8/10

Why is Zoetis stock climbing today?

Zoetis (ZTS) stock rose 2.4% premarket after Q3 2026 earnings beat estimates, with adjusted EPS of $1.75 vs. $1.51 and revenue of $2.4B vs. $2.3B. The company raised full-year EPS guidance to $6.25–$6.35. International sales grew 4%, while U.S. companion animal business faced challenges. The stock traded near $91.30 premarket, below its 52-week high of $132.49.

investing.com